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Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Abstract
Background There are increasing concerns regarding pharmaceutical opioid harms including overdose
and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical
opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment
research has been conducted in people who use heroin. Objectives To assess the effects of maintenance
agonist pharmacotherapy for the treatment of pharmaceutical opioid dependence. Search methods The
search included the Cochrane Drugs and Alcohol Group's Specialised Register of Trials; the Cochrane
Central Register of Controlled Trials (CENTRAL, 2015, Issue 5); PubMed (January 1966 to May 2015);
EMBASE (Ovid) (January 1974 to May 2015); CINAHL (EBSCOhost) (1982 to May 2015); ISI Web of
Science (to May 2014); and PsycINFO (Ovid) (1806 to May 2014). Selection criteria We included
randomised controlled trials examining maintenance opioid agonist treatments that made the following
two comparisons: 1. full opioid agonists (methadone, morphine, oxycodone, levo‐alpha‐acetylmethadol
(LAAM), or codeine) versus different full opioid agonists or partial opioid agonists (buprenorphine) for
maintenance treatment and 2. full or partial opioid agonist maintenance versus placebo, detoxification
only, or psychological treatment (without opioid agonist treatment). Data collection and analysis We used
standard Cochrane methodological procedures. Main results We identified six randomised controlled
trials that met inclusion criteria (607 participants). We found moderate quality evidence from two studies
of no difference between methadone and buprenorphine in self reported opioid use (risk ratio (RR) 0.37,
95% confidence interval (CI) 0.08 to 1.63) or opioid positive urine drug tests (RR 0.81, 95% CI 0.56 to
1.18). There was low quality evidence from three studies of no difference in retention between
buprenorphine and methadone maintenance treatment (RR 0.69, 95% CI 0.39 to 1.22). There was
moderate quality evidence from two studies of no difference between methadone and buprenorphine on
adverse events (RR 1.10, 95% CI 0.64 to 1.91). We found low quality evidence from three studies favouring
maintenance buprenorphine treatment over detoxification or psychological treatment in terms of fewer
opioid positive urine drug tests (RR 0.63, 95% CI 0.43 to 0.91) and self reported opioid use in the past 30
days (RR 0.54, 95% CI 0.31 to 0.93). There was no difference on days of unsanctioned opioid use
(standardised mean difference (SMD) ‐0.31, 95% CI ‐0.66 to 0.04). There was moderate quality evidence
favouring buprenorphine maintenance over detoxification or psychological treatment on retention in
treatment (RR 0.33, 95% CI 0.23 to 0.47). There was moderate quality evidence favouring buprenorphine
maintenance over detoxification or psychological treatment on adverse events (RR 0.19, 95% CI 0.06 to
0.57). The main weaknesses in the quality of the data was the use of open‐label study designs. Authors'
conclusions There was low to moderate quality evidence supporting the use of maintenance agonist
pharmacotherapy for pharmaceutical opioid dependence. Methadone or buprenorphine appeared equally
effective. Maintenance treatment with buprenorphine appeared more effective than detoxification or
psychological treatments. Due to the overall low to moderate quality of the evidence and small sample
sizes, there is the possibility that the further research may change these findings.
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ABSTRACT
Background
There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase
in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin,
yet most opioid agonist treatment research has been conducted in people who use heroin.
Objectives
To assess the effects of maintenance agonist pharmacotherapy for the treatment of pharmaceutical opioid dependence.
Search methods
The search included the Cochrane Drugs and Alcohol Group’s Specialised Register of Trials; the Cochrane Central Register of Controlled
Trials (CENTRAL, 2015, Issue 5); PubMed (January 1966 to May 2015); EMBASE (Ovid) (January 1974 to May 2015); CINAHL
(EBSCOhost) (1982 to May 2015); ISI Web of Science (to May 2014); and PsycINFO (Ovid) (1806 to May 2014).
Selection criteria
We included randomised controlled trials examining maintenance opioid agonist treatments that made the following two comparisons:
1. full opioid agonists (methadone, morphine, oxycodone, levo-alpha-acetylmethadol (LAAM), or codeine) versus different full opioid
agonists or partial opioid agonists (buprenorphine) for maintenance treatment and
2. full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment (without opioid agonist
treatment).
Data collection and analysis
We used standard Cochrane methodological procedures.
Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
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Main results
We identified six randomised controlled trials that met inclusion criteria (607 participants).
We found moderate quality evidence from two studies of no difference between methadone and buprenorphine in self reported opioid
use (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.08 to 1.63) or opioid positive urine drug tests (RR 0.81, 95% CI 0.56 to 1.18).
There was low quality evidence from three studies of no difference in retention between buprenorphine and methadone maintenance
treatment (RR 0.69, 95% CI 0.39 to 1.22). There was moderate quality evidence from two studies of no difference between methadone
and buprenorphine on adverse events (RR 1.10, 95% CI 0.64 to 1.91).
We found low quality evidence from three studies favouring maintenance buprenorphine treatment over detoxification or psychological
treatment in terms of fewer opioid positive urine drug tests (RR 0.63, 95% CI 0.43 to 0.91) and self reported opioid use in the past
30 days (RR 0.54, 95% CI 0.31 to 0.93). There was no difference on days of unsanctioned opioid use (standardised mean difference
(SMD) -0.31, 95% CI -0.66 to 0.04). There was moderate quality evidence favouring buprenorphine maintenance over detoxification
or psychological treatment on retention in treatment (RR 0.33, 95% CI 0.23 to 0.47). There was moderate quality evidence favouring
buprenorphine maintenance over detoxification or psychological treatment on adverse events (RR 0.19, 95% CI 0.06 to 0.57).
The main weaknesses in the quality of the data was the use of open-label study designs.
Authors’ conclusions
There was low to moderate quality evidence supporting the use of maintenance agonist pharmacotherapy for pharmaceutical opioid
dependence. Methadone or buprenorphine appeared equally effective. Maintenance treatment with buprenorphine appeared more
effective than detoxification or psychological treatments.
Due to the overall low to moderate quality of the evidence and small sample sizes, there is the possibility that the further research may
change these findings.

PLAIN LANGUAGE SUMMARY
Opioid maintenance medicines for the treatment of dependence on opioid pain medicines
Background
Use of pharmaceutical opioids (medicines that are used to treat pain) has increased dramatically in some parts of the world since the
mid-1990s. With the increased use, there has been increasing numbers of people seeking treatment for dependence (addiction) on
pharmaceutical opioids. Currently, most treatment guidelines are based on research that was conducted in people who were dependent
on heroin (a highly addictive opioid). This review sought to compare different opioid agonist maintenance treatments (i.e. treatments
such as methadone or buprenorphine that are given for at least 30 days to help the person to reduce their unsanctioned drug use) for
the treatment of pharmaceutical opioid dependence. We also compared results from maintenance treatment to short term treatments
such as detoxification (removal of the drug from the body) or psychological treatments (e.g. talking therapy, counselling).
Study characteristics
We examined the scientific literature up to May 2015. We identified six randomised controlled trials (studies where people were allocated
at random to one of two or more treatment or control conditions) involving 607 people who were dependent on pharmaceutical opioids.
The people in the study were 77% male and had an average age of 31.6 years. The average duration of the studies comparing different
opioid maintenance treatments (three studies that compared methadone to buprenorphine) was 24 weeks, and the average duration
of studies comparing a maintenance treatment (three studies with buprenorphine maintenance) to detoxification or psychological
treatment was 10 weeks. Five of the six studies were conducted in the US, with one study from Iran.
We looked at opioid use and leaving treatment early.
Five of the studies were funded by the National Institute of Health (USA), with one study not reporting the funding source. Four
studies reported that a drug company provided the medicine.
Key results
Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
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We found that there is probably little or no difference between how well methadone and buprenorphine worked to keep people in
treatment, to reduce opioid use, or side effects. We found that buprenorphine probably keeps more people in treatment, may reduce
use of opioids, and has fewer side effects compared to detoxification or psychological treatment alone.
Quality of the evidence
Overall, the evidence was of low to moderate quality. All studies put people into treatment groups randomly, but the participants and
researchers knew which medication the participants were taking, which could bias the results and lower the quality of the evidence.
Some of the studies had reasonable numbers of people who did not finish the study in both treatment groups, which means there are
some missing results, but the number of people with missing results was similar in both treatment groups of the study for most studies.
Most of the studies were similar in design and results were collected in a way that allowed them to compare opioid use and number of
people completing the study.

Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]

Full opioid agonists versus different full opioid agonists or partial opioid agonists (methadone versus buprenorphine) for maintenance
Patient or population: pharm aceutical opioid dependent people
Intervention: m ethadone
Comparison: buprenorphine
Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence Comments
(GRADE)

Opioid use
The m ean opioid use The m ean opioid use in assessed with: days was 2.92 days
the intervention group
of unsanctioned opioid
was 1.41 days lower (3.
use at end of study pe37 lower to 0.55 higher)
riod
Scale f rom : 0 to 30
f ollow-up: m ean 24
weeks

129
(1 RCT)

⊕⊕⊕
M oderate 1

-

Opioid use
Study population
assessed with: positive
urine drug screen f or 436 per 1000
opioids at end of treatm ent
-

RR 0.81
(0.56 to 1.18)

196
(2 RCTs)

⊕⊕⊕
M oderate 1

For 1 study (Saxon
2013) m issing urine
drug screens were
coded as positive; however, sensitivity analyses were conducted
and results were not
changed if this assum ption was not m ade

RR 0.37
(0.08 to 1.63)

155
(2 RCTs)

⊕⊕⊕
M oderate 1

-

Risk with buprenor- Risk with methadone
phine

414 per 1000

Opioid use
Study population
assessed with: self reported opioid use at the
end of the study period
f ollow-up: m ean 24

353 per 1000
(244 to 514)

335 per 1000
(232 to 488)
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weeks
382 per 1000

141 per 1000
(31 to 623)

519 per 1000

Retention
Study population
assessed with: proportion of participants re- 631 per 1000
tained in treatm ent
f ollow-up: m ean 20
weeks
382 per 1000

192 per 1000
(42 to 846)
RR 0.69
(0.39 to 1.22)

360
(3 RCTs)

⊕⊕
Low 12

-

436 per 1000
(246 to 770)

264 per 1000
(149 to 467)

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: conf idence interval; RCT: random ised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

All studies were open label. In addition, one study presented lim ited inf orm ation m eaning that we were unable to assess risk
of bias
2
Signif icant heterogeneity, P value = 0.04; I 2 = 68% when the m eta-analyses included Ahm adi 2003. This is not apparent (1 2 =
2%) when the m eta-analyses included only results f rom Neum ann 2013 and Saxon 2013.
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BACKGROUND

Description of the condition
The non-medical use of, and dependence to, pharmaceutical drugs
has been described as a major health problem. An estimated 26
to 36 million people were using opioids in 2010, with around
half using pharmaceutical opioids (UNODC 2012). There are an
estimated 15.6 million opioid dependent people worldwide, with
the global consumption of opioids considered to be increasing (
WHO 2009). Opioid dependence is a chronic relapsing condition
with significant cost to human life (Hser 2001; Grella 2011).
Dependence on pharmaceutical opioids has been well established
as a problem in the US and Canada (Fischer 2012; Manchikanti
2012). In the USA, pharmaceutical opioids are increasingly used
by young people, and pain medications are second to marijuana
as the drug used by new illicit drug initiates (NSDUH 2011).
Globally, illicit opioid use is a major cause of mortality from both
acute effects of intoxication (e.g. overdose and traffic accidents)
and transmission of blood-borne disease associated with injection
drug use (such as human immunodeficiency virus (HIV) and hepatitis C) (Degenhardt 2011). In the USA, where pharmaceutical
opioid use has been described as an epidemic, pharmaceutical opioid overdose is one of the leading cause of mortality, with deaths
from pharmaceutical opioids exceeding the number of deaths from
heroin and cocaine (Compton 2015). In the USA in 2007, more
people died from prescription opioid overdose than motor vehicle
accidents and suicides (Manchikanti 2012). A more recent trend
of declining mortality from prescription opioids was observed in
young people, while among older adults, mortality has continued to increase (West 2015). Similarly high rates of pharmaceutical opioid use have been described in Canada (Fischer 2012). Although other countries are yet to reach the magnitude of the problems seen in the USA and Canada, there is evidence of increased
pharmaceutical opioid use and harms. One global review identified that pharmaceutical opioid diversion, non-medical use and injection was a considerable problem in the USA, South Asia, South
East Asia, and some European countries (Degenhardt 2007). In
Europe, non-medical use of prescription opioids is documented,
including the problematic use of non-prescription codeine in the
UK and France. However, the risk of a prescription opioid epidemic on the scale of what was observed in North America is
thought to be low (van Amsterdam 2015). An estimated 1.6% to
1.7% of the German population are thought to be dependent on
prescription drugs (Casati 2012). Increasing treatment presentations with prescription and over-the-counter (non-prescription)
codeine opioids are reported in South Africa, where 5% to 8% of
treatment presentations are now associated with over-the-counter
opioid dependence (Weich 2008). Increasing reports of use and
harms with pharmaceutical opioids are also reported in Australia,
with increasing mortality due to oxycodone, and increasing hospital presentations for pharmaceutical opioids including over-the-

counter codeine (Frei 2010; Rintoul 2010; Roxburgh 2011). The
number of hospital poisonings in Australia from pharmaceutical
opioids exceeded heroin in 2004 and has continued to grow every
year, and the number of treatment episodes are increasing, though
heroin dependence remains the main opioid people seek treatment
for (Roxburgh 2011; Nielsen 2015a).

Description of the intervention
Opioid agonist treatments are established to be effective in the
treatment of heroin dependence (Clark 2002; Faggiano 2003;
Mattick 2009; Mattick 2014). The two main opioid agonist treatments that are most widely available are methadone and buprenorphine.
Methadone is well established as a treatment and has a strong
evidence base demonstrating its effectiveness in reducing mortality and substance use, improving physical and mental health
outcomes, reducing criminal activity, and reducing HIV risk and
risk behaviours (Caplehorn 1996; Amato 2005; Gowing 2011;
Gowing 2012; Gowing 2013; Mattick 2014).
Methadone is a synthetic µ-opioid agonist, and an N-methyl-Daspartate (NMDA) antagonist. It has a half-life of 24 to 36 hours
and has close to 100% oral bioavailability. Methadone is generally
given as a single daily dose in the treatment of opioid dependence.
Methadone doses of 60 to 100 mg are more effective in retaining
people in treatment compared with lower doses (Faggiano 2003).
Buprenorphine is a partial opioid agonist, having a lower intrinsic
activity at the opioid receptor, but, due to its high affinity for the
opioid receptor, buprenorphine has antagonist actions, blocking
the effect of other opioids. Buprenorphine has a favourable safety
profile due to its ceiling on respiratory effects (Walsh 1994), with
mortality in treatment appearing to be relatively less common with
buprenorphine compared with methadone in naturalistic study
designs in Australia and France (Auriacombe 2001; Degenhardt
2009). Buprenorphine has poor oral bioavailability, and is available
in sublingual formulations for the treatment of opioid dependence.
Due to its pharmacological properties, buprenorphine is able to
be given as larger doses every second or third day (Amass 2000).
Levo-alpha-acetylmethadol (LAAM) was concluded to be more
effective than methadone for reducing heroin use (Clark 2002),
but it is currently not commercially available. Other therapies such
as slow release oral morphine have also been explored.

How the intervention might work
Opioid agonist treatment, also known as opioid maintenance
treatment, involves prescribing maintenance doses of an opioid
medication in place of the drug of dependence. Most of the original research into opioid maintenance treatment involved prescribing a legal opioid such as methadone or buprenorphine to treat
illicit opioid (e.g. heroin) dependence. The provision of a regular
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dose of a legal opioid treatment enables a reduction in illicit or
unsanctioned opioid use, with improvements in health and social
stability. The dose of the medication is adjusted to a level that reduces withdrawal and craving without causing excessive sedation.
Regular dosing maintains a fairly constant blood level, so that the
sense of euphoria or intoxication usually associated with each dose
of the drug (either illicit or prescribed) is lessened. Maintenance
treatment decreases the frequency and intensity of the cycle of intoxication and withdrawal, allowing the client to address the associated issues necessary for recovery better. Psychosocial support
provided in conjunction with medication can help to address the
psychological health and social problems that can be associated
with opioid use, and therefore help to improve quality of life and
prevent premature mortality (WHO 2009).
Opioid agonist treatment works by provision of a regular dose of
µ-opioid agonist that binds at the µ-opioid receptor, alleviating
opioid withdrawal symptoms. Providing a stable dose of opioid
agonist has been demonstrated to lead to numerous health and
social benefits for opioid dependent people, specifically though
reducing illicit opioid use (Amato 2005; Mattick 2009; Mattick
2014), HIV risk behaviour (Gowing 2011), HIV seroconversion
(MacArthur 2012), and criminality (Amato 2005; Mattick 2009).
It has been confirmed to improve physical and mental health, and
social functioning (Padaiga 2007; Mattick 2009; Mattick 2014),
and reduce mortality (Degenhardt 2011).

agonist treatments in prescription opioid dependence, but a systematic review is yet to be conducted to determine whether similar outcomes can be expected for this new population of opioid
dependent people. This review will fill an evidence gap informing
clinicians about effective approaches using agonist pharmacotherapies for pharmaceutical opioid dependence.

OBJECTIVES
To assess the effects of maintenance agonist pharmacotherapy for
the treatment of pharmaceutical opioid dependence.

METHODS

Criteria for considering studies for this review

Types of studies
Randomised controlled trials (RCTs).
Types of participants

Why it is important to do this review
Opioid agonist treatment is commonly initiated as a first-line treatment for people with pharmaceutical opioid dependence, even
though much of the evidence base for the use of pharmacotherapy
in opioid dependence has been derived from studies conducted
primarily or exclusively with heroin-dependent samples. People
who use pharmaceutical opioids (i.e. both prescription opioids and
over-the-counter opioids such as codeine) have been described in
the literature to be a patient population with a number of characteristics that differ from heroin-using populations, including being more likely to be white, employed, less likely to use drugs by
injection, and having a higher prevalence of physical and mental
health co-morbidities (Brands 2004; Moore 2007; Fischer 2008;
Nielsen 2011; Nielsen 2015a). How these characteristics may impact on treatment outcomes is not well understood. Further, studies that have compared treatment outcomes for people who use
pharmaceutical opioids and heroin have had mixed results, with
some studies finding better treatment outcomes for people using pharmaceutical opioids, and other studies finding no difference (Banta-Green 2009; McCabe 2013; Nielsen 2013; Nielsen
2015b).
Pharmaceutical opioid dependence is at epidemic levels in the
USA and is increasing globally. Establishing an evidence base for
treatment of prescription opioid dependence is therefore timely
and critical. An emerging evidence base exists for the use of opioid

We included studies with people who were assessed by study staff
to meet Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV), International Statistical Classification of
Diseases and Related Health Problems, 10th Revision (ICD-10),
or other validated criteria for pharmaceutical opioid dependence,
or were assessed by a clinician to meet criteria for pharmaceutical
opioid dependence (i.e. a population meeting criteria for ’addiction’ rather than just physiological neuro-adaptation in the absence of other behaviours suggesting dependence).
Pharmaceutical opioid dependent people did not include those
who were solely taking pharmaceutical opioids in the context of
opioid substitution treatment (e.g. studies of people who were already in methadone treatment). Where participants were reported
to be ’opioid dependent’, as opposed to specifically dependent on
pharmaceutical opioids, the main opioid used prior to treatment
entry must have been a pharmaceutical opioid. We excluded studies examining opioid treatments primarily for pain and not for the
treatment of opioid dependence.
Where study populations were not exclusively comprised of primary pharmaceutical opioid dependent people, at least 80% of
the study participants must have reported pharmaceutical opioids
as their primary substance for the parent study data to be included
in the analysis. Where subpopulations of pharmaceutical opioid
dependent people do not comprise 80% of the study population,
we requested data for sub-analysis, with only participants meeting
the above criteria (i.e. dependent on pharmaceutical opioids, or
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opioid dependent with the main opioid used being a pharmaceutical opioid) included in the analysis. We contacted study authors
where necessary to confirm levels of use of pharmaceutical opioids. Studies with mixed populations of opioid dependent people
must have recruited at least 10 people who were dependent on
pharmaceutical opioids for re-analyses of data to be included in
the review.

8. Psychological health, as assessed by validated scales such as
the SF-36 (Ware 1992), Kessler Psychological Distress Scale
(K10) (Kessler 2002), or Depression and Anxiety Stress Scale
(DASS) (Lovibond 1995).
Outcomes were either self reported or objectively measured.

Search methods for identification of studies
Types of interventions
We included studies of maintenance opioid agonist treatments,
where maintenance was defined as at least 30 days of opioid agonist treatment. We included trials that made the following comparisons:
1. full opioid agonists (methadone, morphine, oxycodone,
LAAM, or codeine) versus different full opioid agonists or partial
opioid agonists (buprenorphine) for maintenance treatment;
2. full or partial opioid agonist maintenance versus placebo,
detoxification only, or psychological treatment (without opioid
agonist treatment).
Types of outcome measures
Outcome measures were not considered as part of the eligibility
criteria.
Primary outcomes

1. Illicit opioid use, as measured by: days of unsanctioned
opioid use at the end of the intervention period.
2. Illicit opioid use at end of treatment completion (defined as
point prevalence of opioid use at end of treatment by self report
and with urine drug screen).
3. Retention.
Secondary outcomes

1. Pain, assessed by validated scales such as the Brief Pain
Inventory (Cleeland 1991), and the McGill Pain Questionnaire
(Melzack 1975).
2. Risk behaviours (injecting, sexual, polydrug use, overdoses,
or hospital admissions).
3. Adverse effects (participants experiencing any adverse event,
or serious adverse event).
4. Aberrant opioid related behaviours (e.g. seeing multiple
doctors for extra opioid medication, lost medication,
unauthorised dose escalations).
5. Employment.
6. Quality of life, as assessed by validated scales such the
World Health Organization Quality of Life (WHOQOL) or
WHOQOL-BREF (WHO 1997).
7. Physical health, as assessed by validated scales such as the
36-item Short Form (SF-36) (Ware 1992)

Electronic searches
A search strategy was developed in consultation with a drug and
alcohol research information specialist, and search terms revised
appropriately for each database to take account of differences in
controlled vocabulary and syntax rules (Appendix 1).
We searched:
1. Cochrane Drugs and Alcohol Group’s Specialised Register
of Trials; May 2015;
2. the Cochrane Central Register of Controlled Trials
(CENTRAL, 2015, Issue 5);
3. PubMed (January 1966 to May 2015);
4. EMBASE (Ovid) (January 1974 to May 2015);
5. CINAHL (EBSCOhost) (1982 to May 2015);
6. ISI Web of Science (1900 to May 2014);
7. PsycINFO (Ovid) (1806 to May 2014).
Searching other resources
We search abstracted databases including the National Institute on Drug Abuse/College on Problems of Drug Dependence
(NIDA/CPDD) abstracts, as well as clinical trial registers ClinicalTrials.gov (www.clinicaltrials.gov); World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/en).
We searched the reference lists of all relevant papers to identify
further studies, in addition to contacting the authors of all included studies to enquire if there were other relevant published
or unpublished studies. All searches included English and nonEnglish language literature.

Data collection and analysis
Selection of studies
One review author reviewed the titles and abstracts identified by
the above searches. We requested the full text of each potentially
relevant article, and two review authors independently assessed the
studies for inclusion. Where the two review authors were unable
to reach agreement following their independent review of the full
text, a third review author assessed the studies to assist in reaching
consensus.
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Data extraction and management

Grading the evidence

Two review authors independently extracted data using a data
collection form, with a third review author involved where there
was disagreement to assist in reaching consensus.
We extracted information about the number of participants
treated; drug and dosing regimen; study design; study duration and
follow-up; and outcomes listed at including pain, substance use
measures, treatment retention, risk behaviours, employment, quality of life, physical and psychological health, and adverse events
(participants experiencing any adverse event, or serious adverse
event) from each study and recorded them on a data extraction
sheet.
We attempted to collect and utilise the most detailed numerical
data that might have facilitated similar analyses of included studies. Where 2×2 tables or means and standard deviations were not
available, we used effect estimates (e.g. odds ratios, regression coefficients), confidence intervals (CI), test statistics (e.g. t, F, Z, Chi2 )
or P values in the analyses (see also Measures of treatment effect).

We assessed the overall quality of the evidence for the primary
outcome using the Grading of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) system.
GRADE developed a system for grading the quality of evidence
that takes into account issues not only related to internal validity
but also to external validity, such as directness, consistency, imprecision of results, and publication bias (GRADE 2004; Guyatt
2008; Guyatt 2011). We presented the main findings of the review in the ’Summary of findings’ tables, which present results in
a transparent and simple tabular format. In particular, the tables
provide key information concerning the quality of evidence, the
magnitude of effect of the interventions examined, and the sum
of available data on the main outcomes.
The GRADE system uses the following criteria for assigning grades
of evidence.
1. High: we are very confident that the true effect lies close to
that of the estimate of the effect.
2. Moderate: we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
3. Low: our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
4. Very low: we have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Grading is decreased for the following reasons.
1. Serious (-1) or very serious (-2) limitation to study quality.
2. Important inconsistency (-1).
3. Some (-1) or major (-2) uncertainty about directness.
4. Imprecise or sparse data (-1).
5. High probability of reporting bias (-1).
Grading is increased for the following reasons.
1. Strong evidence of association - significant risk ratio (RR)
of greater than 2 (less than 0.5) based on consistent evidence
from two or more observational studies, with no plausible
confounders (+1).
2. Very strong evidence of association - significant RR of
greater than 5 (less than 0.2) based on direct evidence with no
major threats to validity (+2).
3. Evidence of a dose response gradient (+1).
4. All plausible confounders would have reduced the effect
(+1).

Assessment of risk of bias in included studies
We performed the risk of bias assessment for RCTs using the criteria recommended by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). This comprises a two-part
tool addressing seven specific domains, namely sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome
assessor (detection bias), incomplete outcome data (attrition bias),
selective outcome reporting (reporting bias), and other sources of
bias. The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool
involves assigning a judgement relating to the risk of bias for that
entry, in terms of low, high, or unclear risk. To make these judgements, we used the criteria indicated by the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), adapted to
the addiction field. See Appendix 2 for details.
The tools addressed the domains of sequence generation and allocation concealment (avoidance of selection bias) by a single entry
for each study.
We considered blinding of participants, personnel, and outcome
assessor (avoidance of performance bias and detection bias) separately for objective outcomes (e.g. retention, substance use measured by urine analysis, participants relapsed at the end of followup, participants engaged in further treatments) and subjective outcomes (e.g. duration and severity of signs and symptoms of withdrawal, participant self reported use of substance, adverse effects,
social functioning as integration at school or at work, family relationship).
We considered incomplete outcome data (avoidance of attrition
bias) for all outcomes except for retention, which is often the
primary outcome measure in trials on addiction.

Measures of treatment effect
Where possible, we expressed the treatment effect for each dichotomous outcome as a risk ratio (RR) with 95% confidence
intervals (CI). Where there was a comparable consistent outcome
measure (e.g. days of opioid use), we expressed the treatment effect for each continuous outcome as a mean difference (MD) with
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95% CIs. Where there was variability in outcome measure (e.g.
quality of life scales, risk behaviour measures, or pain scales), we
expressed the treatment effect for each continuous outcome as a
standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
For trials with multiple treatment arms, we combined groups to
allow single pair-wise comparisons.
Dealing with missing data
Where there appeared to be an important amount of missing data,
we described the possible effects of the missing data in the ’Discussion’ section and ’Summary of findings’ tables.

meta-analysis was not possible, we reported a narrative synthesis
of the findings.
Subgroup analysis and investigation of heterogeneity
The search did not identify a sufficient number of studies to enable
planned subgroups of participants to be examined and investigated
for potential sources of heterogeneity:
1. with and without chronic pain;
2. with and without a history of heroin use;
3. with and without a history of injecting drug use;
4. with and without mental health problems.
We will consider the possibility of subgroup analyses when we
update the review and additional studies are available.
Sensitivity analysis

Assessment of heterogeneity
We considered clinical heterogeneity (variability in the participants, interventions, and outcomes studied) and methodological
heterogeneity (variability in study design and risk of bias), which
we discussed in the ’Summary of findings’ tables.
We conducted meta-analysis were studies were sufficiently homogeneous in terms of participants, interventions, and outcomes to
provide a meaningful summary. Where this was not the case, and
the heterogeneity of the included studies precluded a meta-analysis being performed, we described the relevant studies separately.
To assess heterogeneity, initially we inspected the results graphically. A P value of the test lower than 0.10 or an I2 statistic of at
least 50% indicated significant statistical heterogeneity.

Where the effect of a decision on the outcome of the review was
uncertain (e.g. the decision to include or exclude a study remained
unclear, or the impact of unavailable data on the findings was
uncertain), we conducted a sensitivity analysis with the results
described in text.
To incorporate risk of bias assessment in the review process, we
planned to plot intervention effect estimates for different outcomes stratified for risk of bias for each item; however, we found
insufficient numbers of studies to warrant this process for the two
planned comparisons. For future updates of this review, if differences in results are present among studies at different risk of bias,
we will perform sensitivity analysis, excluding studies at a high risk
of bias. We will also perform subgroup analysis for studies at a low
and unclear risk of bias.

Assessment of reporting biases
We planned to use funnel plots (plots of the effect estimate from
each study against the standard error) to assess the potential for
bias related to the size of the trials, which could indicate possible
publication bias. As the search identified too few studies to be
included in a meta-analysis, we did not use funnel plots. In future
updates of this review if sufficient studies are included in metaanalyses (i.e. more than 10), we will use funnel plots.

RESULTS

Description of studies
See Characteristics of included studies table.
Results of the search

Data synthesis
We summarised the key findings of studies descriptively before
considering if studies were appropriate for quantitative meta-analysis. We contacted study authors where we required additional information to enable inclusion of studies in meta-analyses.
We undertook statistical analysis using Review Manager 5 (
RevMan 2012).
We combined the outcomes of the individual trials through metaanalysis where possible (depending on the comparability of interventions and outcomes between trials) using of a random-effects model as variability was expected between the studies. Where

We identified 9076 studies through the electronic and other
searches. After removing duplicates, 6515 titles and abstracts remained. We examined the full text or contacted study authors (or
both) of 49 records, excluding 43 records at this stage, identifying six studies to be included in the analysis (See Figure 1). Several full texts that were reviewed indicated studies had recruited
populations of ’opioid dependent people’ without specifying the
primary opioid used (e.g. whether the participant was dependent
on a pharmaceutical opioid, heroin, or opium). In each of these
papers, where the full text did not explicitly indicate that the participants were dependent on pharmaceutical opioids, the review
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authors (SN, BL) contacted the study authors to determine if the
study met eligibility criteria with respect to the opioid used being
a pharmaceutical opioid. We included studies where the primary
opioid of concern was clearly identified as a pharmaceutical opioid
or where the study population included at least 10 participants that
were dependent on pharmaceutical opioids and data were available to enable analyses of the study data only for those participants
that were dependent on pharmaceutical opioids. Where authors
were unable to provide further information on the primary drug
of concern (other than being an opioid), or where we received no
response, we did not include the study.
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Figure 1. Study flow diagram.
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Included studies
We identified six RCTs that met the inclusion criteria (607 participants). Three studies compared methadone and buprenorphine
(Ahmadi 2003; Neumann 2013; Saxon 2013), and three studies compared buprenorphine maintenance to either buprenorphine taper (in addition to psychological treatment) (Woody
2008; Fiellin 2014) or brief intervention and referral to treatment
(D’Onofrio 2015). The mean duration of the trials was 105 days.
Five of the six studies were conducted in an outpatient setting.
One study recruited participants who were admitted to hospital,
with one group randomised to commence buprenorphine as an
inpatient while the other two groups offered a brief intervention
and treatment referral information (D’Onofrio 2015). Neumann
2013 recruited a population of people with chronic non-cancer
pain and opioid dependence. All other studies recruited participants with dependence on pharmaceutical opioids, and one study
specifically recruited participants that were injecting buprenorphine (Ahmadi 2003).
Data from three studies were re-analyses of parent studies to include only data from participants who were dependent on pharmaceutical opioids; two studies provided data for analyses through
the CTN data share website (Woody 2008; Saxon 2013), and
for one study, the study statistician provided the data for participants who were dependent on pharmaceutical opioids (D’Onofrio
2015). Fiellin 2014 also provided additional data to facilitate analyses with comparable outcome measures across the studies. Data
for two studies were drawn directly from the published papers
(Ahmadi 2003; Neumann 2013).
Five studies were conducted in the US and one study was conducted in Iran (Ahmadi 2003). Five studies recruited adults, and
one study examined young people aged 15 to 21 years (Woody
2008).
Overall, the participants in the studies were 77% male and had a
mean age of 31.6 years. The mean duration of the studies comparing different opioid maintenance treatments (three studies that
compared methadone to buprenorphine) was 24 weeks, and the
mean duration of studies comparing a maintenance treatment

(three studies with buprenorphine maintenance) to detoxification
or psychological treatment was 10 weeks.

Excluded studies
Of the studies that we excluded during full text review, we excluded
three studies because all participants received the same opioid agonist (or partial agonist) medication, meaning that no comparison
was possible: one study of buprenorphine for prescription opioid
dependence because the study was an adaptive study design where
the randomised trial component compared adjunctive counselling
to standard care, and all participants received buprenorphine (resulting in there being no non-opioid agonist comparison group)
(Weiss 2011). Fiellin 2006 described that all participants received
buprenorphine, hence there was no non-agonist arm for comparison. Chopra 2009 also examined different psychosocial adjunct
treatments where all participants received buprenorphine.
Four studies contained prescription opioid dependent people in
their population, but the number was too small (e.g. two or three
participants) to permit meaningful analyses of the prescription
opioid dependent participants across different treatment conditions (Liebschutz 2013), or dependence to pharmaceutical opioids
was unable to be confirmed where participants were using multiple opioids (Strain 1996; Kristensen 2005; Piralishvili 2015). Two
further studies recruited pharmaceutical opioid dependent participants to the study; we requested data to perform analyses for only
those dependent on pharmaceutical opioids but they were not
available at the time of this review (Ling 2010; Rosenthal 2013).
Three studies did not administer maintenance opioid agonists (
Stitzer 1983; Amass 1994; Sigmon 2013), and three studies were
not RCTs (Batki 1998; Gossop 2001; Hoffmann 2014).
The remainder of the excluded studies had populations of opioid
dependent people primarily using heroin (see Excluded studies).

Risk of bias in included studies
Figure 2 and Figure 3 present a summary of the assessed risk of
bias for each of the included studies.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
No studies had high risk of selection bias. All included studies
were RCTs. For two studies, the method of sequence generation
was unclear (Ahmadi 2003; Saxon 2013), and for three studies,
the method of allocation concealment was unclear (Ahmadi 2003;
Neumann 2013; Saxon 2013). The remaining studies had low risk
of random sequence or allocation bias.
Blinding
None of the studies were double blinded studies (most studies were
described as open-label studies), with all studies having either a
high or unknown risk of bias.
Incomplete outcome data
All studies reported data on retention. For other outcomes measures, some studies only presented data on treatment completers
(Neumann 2013), or had differences in the number of participants retained across groups, which potentially introduced bias
(Fiellin 2014; D’Onofrio 2015). Two studies had a low risk of bias
(Woody 2008; Saxon 2013).

Full opioid agonists versus different full opioid
agonists or partial opioid agonists
We found three studies, all comparing methadone versus
buprenorphine (with or without naloxone) (Ahmadi 2003;
Neumann 2013; Saxon 2013). We found no studies examining
opioids agonists other than methadone or buprenorphine.
Primary outcomes

Illicit opioid use
There was no significant difference in days of unsanctioned opioid use (MD -1.41 days, 95% CI -3.37 to 0.55; one study; 129
participants) (Analysis 1.1).
There was no significant difference in point prevalence use at the
end of treatment (urine-analysis results) (RR 0.81, 95% CI 0.56
to 1.18; two studies; 196 participants) (Analysis 1.2).
There was no significant difference in point prevalence use at the
end of treatments (self reported)(RR 0.37, 95% CI 0.08 to 1.63;
two studies; 155 participants) (Analysis 1.3).
Retention

Selective reporting
Four studies had a low risk of reporting bias, with prospectively
published protocols available or prospective clinical trial registration including describing main outcome measures or data published on open access websites, or a combination of these (Woody
2008; Neumann 2013; Saxon 2013; D’Onofrio 2015). One study
only reported on one outcome measure, retention (Ahmadi 2003).

Effects of interventions
See: Summary of findings for the main comparison Full opioid
agonists versus different full opioid agonists or partial opioid
agonists (methadone versus buprenorphine) for maintenance;
Summary of findings 2 Full or partial opioid agonist maintenance
versus placebo, detoxification only or psychological treatment
(buprenorphine maintenance compared to taper or treatment as
usual)
See Summary of findings for the main comparison; Summary of
findings 2. We presented results for the two main comparisons:
1. opioid agonists versus other opioid agonists (or partial
agonists) for maintenance treatment;
2. full or partial opioid agonists versus placebo, detoxification,
or psychological treatment (without maintenance agonist
treatment).
The results in the ’Summary of findings’ tables include the primary
outcomes measures of opioid use and retention in treatment.

There was no significant difference in retention (number of participants retained at end of treatment) (RR 0.69, 95% CI 0.39 to
1.22; three studies; 360 participants) (Analysis 1.4).
Secondary outcomes

Pain
Two studies with 152 participants found no significant difference in pain using different measures (improvement from baseline
pain and mean bodily pain). They found no significant difference
(SMD 0.11, 95% CI -0.22 to 0.43) (Analysis 1.5).
Risk behaviours
One study with 170 participants found no significant difference in
risk behaviours (RR 0.52, 95% CI 0.02 to 12.64) (Analysis 1.6).
Adverse effects
Two studies examined adverse effects but in different ways:
Neumann 2013 described self reported adverse effects and serious
adverse events, Saxon 2013 examined serious adverse effects. The
two studies, with data from 196 participants, found no significant
difference (RR 1.10, 95% CI 0.64 to 1.91) (Analysis 1.7).
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Aberrant opioid related behaviours

Retention

None of the studies reported aberrant opioid related behaviours.

There was a significant difference in favour of buprenorphine
maintenance treatment for retention (number of participants retained at end of treatment) (RR 0.33, 95% CI 0.23 to 0.47; three
studies; 247 participants) (Analysis 2.4).

Employment
None of the studies reported on employment.
Quality of life

Secondary outcomes

None of the studies reported an overall quality of life score.
Pain
Physical health
One study found no significant difference in mean physical functioning (SF-36) (MD 1.28, 95% CI -3.83 to 6.39; 127 participants) (Analysis 1.8).
Psychological health
One study found no significant difference in mental health functioning (SF-36) (MD -2.13, 95% CI -10.06 to 5.80; 127 participants) (Analysis 1.9).
Full or partial opioid agonist maintenance versus
placebo, detoxification only, or psychological
treatment (without opioid agonist treatment)
We found three studies, all comparing buprenorphine maintenance treatment to a control condition. We found no studies using
other opioid agonist treatment compared to a non-agonist control
group.

Primary outcomes

There was no significant difference in the proportion of participants who reported ’moderate’ or ’extreme’ pain or discomfort at
week eight (RR 0.52, 95% CI 0.27 to 1.01; one study; 36 participants)(Analysis 2.5).

Risk behaviours
There was no significant difference in events of injecting risk behaviour (RR 0.38, 95% CI 0.04 to 3.54; two studies; 98 participants) (Analysis 2.6).

Adverse effects
Outcomes were measured differently across two studies, one study
reported protective transfers Fiellin 2014 and one study reported
serious adverse events Woody 2008. 166 participants: with findings favouring the buprenorphine maintenance (RR 0.19, 95%CI
0.06, 0.57). See Analysis 2.7.

Aberrant opioid related behaviours
None of the studies reported aberrant opioid related behaviours.

Illicit opioid use
There was no significant difference in days of unsanctioned opioid
use (reported as mean days in past 7 or 30 days: SMD -0.31; 95%
CI -0.66 to 0.04; two studies; 133 participants) (Analysis 2.1).
There was a significant difference in favour of buprenorphine
maintenance treatment for point prevalence use at the end of treatment (urine-analysis results) (RR 0.63, 95% CI 0.43 to 0.91; three
studies, 206 participants) (Analysis 2.2).
There was a significant difference in favour of buprenorphine
maintenance treatment for point prevalence use at the end of treatments (self reported) RR 0.54, 95% CI 0.31 to 0.93; three studies, 204 participants). When the analysis excluded results from
Woody 2008 due to evidence of heterogeneity (degrees of freedom
(df ) = 2; P value = 0.12; I2 = 52%) the result of the meta-analyses
was unchanged favouring buprenorphine maintenance (RR 0.66,
95% CI 0.49 to 0.89; two studies; 177 participants; P value =
0.81; I2 = 0%) (Analysis 2.3).

Employment
None of the studies reported on employment.

Quality of life
None of the studies reported an overall quality of life measure.

Physical health
There was a significant difference in favour of buprenorphine
maintenance treatment for mean ratings of physical health on the
EQ Visual Analogue Scale (a scale of self reported health state out
of 100) at week eight (MD 31.08, 95% CI 12.40 to 49.76; one
study; 36 participants) (Analysis 2.8).
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Psychological health
There was no significant difference in proportions of participants
reporting moderate or extreme anxiety and depression (as measured with the EQ-5D (EuroQol five dimensions questionnaire))
at week eight (RR 0.89, 95% CI 0.53 to 1.50; one study; 36 participants) (Analysis 2.9).

Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]

Full or partial opioid agonist maintenance versus placebo, detoxification only or psychological treatment (buprenorphine maintenance compared to taper or treatment as
usual)
Patient or population: pharm aceutical opioid dependent people
Intervention: opioid agonist
Comparison: detoxif ication/ placebo
Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence Comments
(GRADE)

Days of unsanctioned The m ean days of un- The m ean days of un- opioid use
sanctioned opioid use sanctioned opioid use
assessed with: num - was 1.06 days
in the intervention
ber of days of unsancgroup was 0.31 stantioned use (as num ber
dard deviations days
of days/ 30 or days/ 7)
lower (0.66 lower to 0.
Scale f rom : 0 to 7 or 30
04 higher)
f ollow-up: m ean 10
weeks

133
(2 RCTs)

⊕⊕
Low 12

-

Self reported opioid use Study population
at treatm ent com ple596 per 1000
tion
f ollow-up: m ean 10
weeks
-

204
(3 RCTs)

⊕⊕
Low 12

Som e heterogeneity in
results, which is likely
to be attributed to the
dif f erent populations (i.
e. non-treatm ent seeking), and indirect nature
of substance use outcom es in the study by
D’Onof rio 2015

Risk with detoxifica- Risk with Opioid agotion/ placebo
nist

737 per 1000

RR 0.54
(0.31 to 0.93)
322 per 1000
(185 to 554)

398 per 1000
(228 to 685)
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Opioid use
Study population
assessed with: urine
615 per 1000
drug screens
f ollow-up: m ean 10
weeks
500 per 1000

⊕⊕
Low 12

-

RR 0.33
(0.23 to 0.47)

247
(3 RCTs)

⊕⊕⊕
M oderate 1

Som e
heterogeneity
was identif ied in populations, of note is that
the study by Ahm adi
2003 recruited people who were injecting
buprenorphine, and predom inantly had histories of opium or heroin
use prior to buprenorphine. Results were
not changed when the
analyses excluded this
study (i.e. no dif f erence
between buprenorphine
and m ethadone when
this study was included
or excluded)

315 per 1000
(215 to 455)

208 per 1000
(145 to 297)

769 per 1000

206
(3 RCTs)

387 per 1000
(264 to 559)

Retention
Study population
assessed with: proportion of participants retained in treatm ent
f ollow-up: m ean 10
weeks

631 per 1000

RR 0.63
(0.43 to 0.91)

254 per 1000
(177 to 362)

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: conf idence interval; RCT: random ised controlled trial; RR: risk ratio.
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
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Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

Studies were open label, dif f erences in retention were reported between the groups resulting in dif f erences in m issing data
on som e variables.
2 One study was exam ining dif f erent m ethods of ref erral to treatm ent in non-treatm ent seeking people who presented to
hospital. Substance use was an indirect outcom e of the study as this was not the prim ary f ocus.
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DISCUSSION

Summary of main results
The studies identified compared methadone versus buprenorphine
maintenance treatment (three studies), and buprenorphine maintenance treatment versus detoxification or psychological treatment
(without maintenance agonist treatment); two studies where the
comparison was buprenorphine taper and one study where the
control condition was brief intervention and referral). In total,
the review included six studies with 604 participants. The quality
of the evidence was generally low to moderate (see Summary of
findings for the main comparison; Summary of findings 2) with all
studies being RCTs that were not double blind. Sample sizes were
generally small, from 53 to 204 participants. The meta-analyses
included data for both comparisons for the primary outcomes of
opioid use and retention.
There was moderate quality evidence finding no significant differences in self reported opioid use or opioid positive urine drug tests
between methadone and buprenorphine. There was low quality
evidence that there was no difference in retention between methadone and buprenorphine. These are commonly considered some
of the important outcomes for treatment of pharmaceutical opioid dependence. As evidence did not favour either of these treatments, other clinician or treatment system factors may contribute
to the choice of pharmacotherapy for patients, including patient
preference, safety, and availability of medications.
Where buprenorphine maintenance was compared with detoxification or other psychological treatment (in the absence of maintenance opioid pharmacotherapy), low to moderate quality evidence
favoured maintenance buprenorphine treatment with less self reported opioid use and fewer opioid positive urine tests combined
with greater retention. These findings suggest that where retention
and substance outcomes are important to patient and clinician,
there appear to be advantages in maintenance agonist treatment.

Overall completeness and applicability of
evidence
There was enough consistency in the way the studies collected and
reported primary outcome measures to enable pooling data on
the key outcomes measures. Missing data introduced the potential
for bias in opioid use outcome measures. An important limitation
to generalisability is study location. Five of the six studies were
conducted in the US, making it difficult to know how these findings may apply to people dependent on pharmaceutical opioids in
other settings.

Quality of the evidence

The studies in this review were generally either small or the sample
size was small once the population was restricted to only people
that were dependent on pharmaceutical opioids. Two studies had
larger sample sizes; Saxon 2013 (170 participants in the analyses of only pharmaceutical opioid dependent people) and Ahmadi
2003 (204 participants, although this study reported only one outcome). The study by Ahmadi 2003 contributed around one-third
of the sample size, and represented a population of buprenorphine
injectors. As such, the population in this study may differ from
the populations of the other two studies. Sensitivity analyses confirmed that the exclusion of this study did not change the overall
result of the meta-analyses. No studies had high risk of selection
bias, though none of the studies were double blinded. Four out of
six studies had low risk of reporting bias. See Figure 2 and Figure
3.
One of the studies had the primary outcome of ’enrolment in addiction treatment 30 days after randomisation’, as the study was
examining commencing buprenorphine as an inpatient versus two
other conditions where participants received some form of brief
intervention and referral to addiction treatment (these two other
non-buprenorphine groups were combined in the present analyses) (D’Onofrio 2015). As such, the evidence from this study on
opioid use outcomes could be considered indirect as the study did
not directly aim to reduce opioid use. Finally, data for three of the
six studies were drawn from existing larger studies of opioid dependent people, rather than from studies specifically developed to
examine the effectiveness of these interventions for pharmaceutical
opioid dependent people (Woody 2008; Saxon 2013; D’Onofrio
2015).

Potential biases in the review process
There is the possibility that studies with negative findings on pharmacotherapy may be less likely to be published, which could potentially favour the finding of published studies that demonstrate
an effect of pharmacotherapy treatments. We identified no conference abstracts of unpublished studies to confirm if this is the
case.

Agreements and disagreements with other
studies or reviews
The finding of no difference in retention between methadone and
buprenorphine is in contrast to findings reported in studies of
predominantly people dependent on heroin, where Mattick 2014
found evidence in favour of methadone retaining more participants in treatment. Due to the small sample sizes in this review,
there is the possibility that the review was underpowered to detect
a difference.
Findings appear consistent with a larger adaptive study design
that also appeared to favour longer periods of buprenorphine
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treatment, with poorer outcomes following buprenorphine taper
among pharmaceutical opioid dependent people (Weiss 2011).

AUTHORS’ CONCLUSIONS
Implications for practice
There was low quality evidence supporting the use of maintenance
agonist pharmacotherapy for pharmaceutical opioid dependence.
The current data suggest that methadone or buprenorphine are
equally effective. As evidence did not favour either of these treatments over the other, other clinician or treatment system factors
may contribute to the choice of pharmacotherapy for patients, including patient preference, safety, and availability of medications.
Maintenance treatment with buprenorphine may be more effective
than detoxification or psychological treatments (or both).
Due to the overall low to moderate quality of the evidence and
smaller sample sizes, there is the possibility that the further research
may change these findings.

Implications for research
There is a high prevalence of chronic pain among pharmaceuti-

cal opioid dependent people (Lusted 2013); however, only one
small study examined outcomes among people with concurrent
pain and opioid dependence (Neumann 2013). Larger studies
are needed to examine all outcomes, and particularly for people
with pain and opioid dependence, in addition to including standardised measures of pain severity and pain interference as secondary outcomes measures in randomised controlled trials of opioid treatments where populations with pain are recruited (Turk
2008). Growing evidence supports the use of multi-modal treatment strategies for pain, as opposed to relying solely on opioids
for pain management. Expanding the evidence for non-drug and
adjuvant medication strategies to reduce the reliance on opioids
for pain management will be important areas for future work. In
addition, studies that specifically recruit pharmaceutical opioid
dependent people will add to the evidence base that is currently
formed in large part by secondary data analyses from previously
completed clinical trials.
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by year of study]
Ahmadi 2003
Methods

Open label randomised controlled trial

Participants

Participants had reported daily buprenorphine injection for at least 6 months. Most
(80%) had a history of heroin or opium dependence prior to buprenorphine injection.
All participants were male, mean age of 31.2 years (range 17-53). No current use of
substances was reported

Interventions

Methadone 50 mg (n = 68)
Buprenorphine 5 mg (n = 68)
Naltrexone 50 mg (n = 68)
For 12 weeks

Outcomes

Retention

Notes

No other outcome measures reported. A second publication appeared to report findings
from the same study. Included only the first publication on the study. Funding for the
study not reported

Risk of bias
Bias

Risk of bias
Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Insufficient information was provided to enable assessment

Allocation concealment (selection bias)

Unclear risk

Insufficient information was provided to enable assessment

Blinding of participants and personnel Unclear risk
(performance bias) Objective measures

Insufficient information was provided to enable assessment

Blinding of outcome assessor (detection Unclear risk
bias) Subjective outcomes

Insufficient information was provided to enable assessment

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information was provided to enable assessment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Insufficient information was provided to enable assessment

Selective reporting (reporting bias)

High risk

Information was only reported on retention
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Woody 2008
Methods

Open label randomised controlled trial of buprenorphine (+ naloxone) maintenance
compared with buprenorphine detoxification

Participants

Opioid dependent youths (aged 15-21 years). Analyses from unpublished data reported
represents only those participants (n = 53) who reported that a pharmaceutical opioid
was their main drug problem. Mean age of participants reporting pharmaceutical opioid
as a main drug problem 20.0 (SD 1.3) years old, and 64% male

Interventions

Buprenorphine-naloxone + counselling (n = 27) for 12 weeks
Buprenorphine detoxification + counselling (n = 26) for 14 days

Outcomes

Main outcome measure was opioid positive urine tests at weeks 4, 8, and 12

Notes

All outcomes reported in this analysis were for week 8 as buprenorphine taper began in
week 9, meaning at week 12 participants were no longer in maintenance treatment
Disclosures: Quote: “Dr Woody reported being a member of the RADARS [Researched
Abuse, Diversion and Addiction-Related Surveillance] postmarketing study external advisory group whose job is to assess abuse of prescription medications. Denver Health
administers RADARS and Abbott, Cephalon, Endo, Pricara/Ortho-McNeil, Purdue
Pharma, and Shire subscribe to its data. Dr Woody reported that Ortho-McNeil and
Purdue Pharma funded similar work by him prior to his joining RADARS. Dr Woody
reported that Schering-Plough, the European distributor for buprenorphine-naloxone,
funded his travel costs to meetings in Sweden and Finland in June 2008 to present data
from this study. Dr Bogenschutz reported receiving research funding from Forest and
Lilly and having a confidentiality agreement with Lilly. Dr Forman reported being a
faculty member at the University of Pennsylvania and co-principal investigator with Dr
Woody on the Delaware Valley Node of the NIDA Clinical Trials Network until December 2005 when he joined Alkermes. Dr Patkar reported being a consultant to BristolMeyers Squibb, GlaxoSmithKline, and Reckitt Benckiser and being on the speakers’ bureau for and receiving honoraria from Bristol-Meyers Squibb, Forest, GlaxoSmithKline,
Janssen, Jazz Pharmaceuticals Lundbeck, McNeil Consumer & Specialty Inc, Organon,
and Pfizer. Dr Publicker reported having been a speaker for Cephalon, Forest, and Reckitt
Benckiser. Dr McNicholas reported having conducted training programs to certify physicians in the use of buprenorphine. Her expenses have been paid by unrestricted grants
to universities that were often provided by Reckitt Benckiser. Dr Fudala reported having
been employed by the University of Pennsylvania and Philadelphia VA Medical Center
from 1991 until he joined Reckitt Benckiser in June 2005 and reported having
been a consultant to Johnson & Johnson and Purdue Pharma”
This study was supported by the NIDA and Reckitt Benckiser provided medication for
the study

Risk of bias
Bias

Risk of bias
Authors’ judgement

Random sequence generation (selection Low risk
bias)
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Quote: “Randomization occurred through
an automated 24-hour service at the Veterans Affairs Cooperative Studies Program
in Perry Point, Maryland, that was pro30

Woody 2008

(Continued)

grammed to randomise patients separately
by site”
Allocation concealment (selection bias)

Low risk

Central randomisation procedures described above, condition could not be foreseen by staff

Blinding of participants and personnel High risk
(performance bias) Objective measures

Quote: “Research assistants likely know
group assignments because the study was
not blinded”
Open label study

Blinding of outcome assessor (detection High risk
bias) Subjective outcomes

Quote: “Research assistants likely know
group assignments because the study was
not blinded”
Open label study

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Quote: “Research assistants likely knew
group assignments because the study was
not blinded”

Incomplete outcome data (attrition bias)
All outcomes

Investigators used multiple statistical approaches to examine the impact of missing
data on their results and it appears the results of these analyses did not alter the results of the study findings
Quote: “A pattern-mixture model was used
to assess the impact of missing data on
urine test results. Pattern mixture models
extend the basic repeated measures by including a variable that describes the main
patterns of missing data as a main effect and
an interaction with other variables (week
and group). Significant interactions with
the missing data indicator on the main variables suggest that its effects differ across
levels of missing data and that missing
data may not be ignorable. Following suggested guidelines,23 we used time of last
data provision (a categorical variable representing week 4, 8, or 12) as the missing variable. Another approach often taken
is to impute missing tests as positive. If
results obtained for the original and imputed models differ substantially, missing
data may not be ignorable. Both methods were used to evaluate the effects of
data on the primary outcome wherein miss-

Low risk
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Woody 2008

(Continued)

ing urine test results were counted as opioid positive. A GEE [generalised estimating equation] model that ignored missing
data showed a marginal group × time interaction ( = 4.93, P = .09). While not attaining the usual 5% significance, it likely
reflected a lack of power for interaction effects rather than constant treatment effects
at each time point.” “Because there were no
interactions pertaining to dropout time, results suggested that missing data were not
invalidating the group effect”
Selective reporting (reporting bias)

Low risk

Protocol and data were available on an open
access datashare website

Saxon 2013
Methods

Open label randomised controlled trial of methadone vs. buprenorphine

Participants

Reported analyses of unpublished data only for participants that used only pharmaceutical opioids in the 30 days prior to the study (n = 170). Sample was 61% (n = 104)
male, mean age 34.4 years (SD 10.1) at baseline and 83% white with no difference
between randomisation groups on demographic characteristics. Participants who were
randomised to the buprenorphine group were less likely to report a history of heroin
use (odds ratio 0.465, 95% confidence interval 0.25 to 0.88). Past year dependence on
other substance was as follows: alcohol 7% (n = 11), cannabis 7% (n = 12), cocaine 8%
(n = 14), amphetamines 7% (n = 11), sedatives 7% (n = 12)

Interventions

Methadone (n = 66)
Buprenorphine (n = 104)
24 weeks in a flexible dose schedule

Outcomes

Primary outcome of the parent study was liver function at 24 weeks

Notes

Financial interests disclosed. Quote: ”Andrew Saxon: Paid consultant to Reckitt
Benckiser Pharmaceuticals; Walter Ling: Paid consultant to Reckitt Benckiser Pharmaceuticals; R. Douglas Bruce: Research grant support from Gilead Sciences, Inc., Merck
& Co., Bristol Myers Squibb, Boehringer Ingelheim, Reckitt Benckiser Pharmaceuticals,
Abbott Laboratories, Pfizer, Inc., and honorarium from Reckitt Benckiser Pharmaceuticals; Yuliya Lokhnygina: Paid consultant to Johnson & Johnson
Reckitt Benkiser provided some initial advice on the study design and supplied Suboxone.
The main study funding came from the
NIDA through the Clinical Trials Network

Risk of bias
Bias

Risk of bias
Authors’ judgement
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Saxon 2013

(Continued)

Random sequence generation (selection Unclear risk
bias)

Study stated randomisation, no additional
information reported on sequence generation

Allocation concealment (selection bias)

Method of concealment not described

Unclear risk

Blinding of participants and personnel High risk
(performance bias) Objective measures

Study reported to be an open label study

Blinding of outcome assessor (detection High risk
bias) Subjective outcomes

Study reported to be an open label study

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Study reported to be an open label study

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Figure 1 of the publication indicated that
there was more missing data from the
buprenorphine group; however, in the subanalyses, retention was comparable across
the groups suggesting that this was less
likely to influence the results presented in
this review

Selective reporting (reporting bias)

Low risk

Study protocol was available and expected
results were reported. Further, study data
available on datashare website

Neumann 2013
Methods

Open label randomised controlled trial

Participants

Participants eligible for randomisation were men and women aged ≥ 18 years with well
documented chronic non-malignant pain related to the spine or a large joint (e.g. hip,
knee, shoulder) and an addiction to prescription opioids. The sample (n = 54) was 54%
(n = 29) men, mean age 38.3 years (SD 9.7). 7 participants reported cocaine use at
baseline and 20 (36%) had a urine drug test that was positive for any other drug at
baseline

Interventions

Sublingual buprenorphine/naloxone 4-16 mg/1-4 mg/day (experimental group) (n = 26)
Oral methadone tablets 10-60 mg/day (active comparator group) (n = 28); doses were
divided 1-4 times daily

Outcomes

Pain and opioid use

Notes

Results were reported for treatment completers only
The study was supported, in part, by a grant from the NIDA. Conflicts of interest were
not reported in the manuscript
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Neumann 2013

(Continued)

Risk of bias
Bias

Risk of bias
Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Participants were randomised into 1 of 2
groups that were pre-determined by drawing
lots using a 3:3 ratio block randomisation procedure

Allocation concealment (selection bias)

Method of concealment not described

Unclear risk

Blinding of participants and personnel High risk
(performance bias) Objective measures

Quote: “This is a preliminary study ...that
was not a double-blind and double-dummy
study.” “This was an open-label trial without
a placebo and a control group. The outcomes
might have been different, if a placebo had
been used and the treatment conditions were
masked to the participants, to the clinicians
who provided care, and to the investigators
who collected the follow-up data”
No blinding was described

Blinding of outcome assessor (detection High risk
bias) Subjective outcomes

As above, open label study

Blinding of outcome assessment (detection High risk
bias)
All outcomes

As above, open label study

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Analyses only for completers; however, missing data balanced across the 2 intervention
groups (n = 15/28 missing for methadone
group and n = 13/26 missing for buprenorphine group), 13 completers in each group

Selective reporting (reporting bias)

Low risk

Outcomes
were
consistent
with
those prospectively reported on clinicaltrials.
gov NCT00879996

Fiellin 2014
Methods

Open label office-based trial of buprenorphine taper compared to buprenorphine maintenance

Participants

People who were prescription opioid dependent, mean age 30.35 years (SD 9.16), 58%
male. At baseline cocaine abuse was reported by 12% (n = 13)
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Fiellin 2014

(Continued)

Interventions

Buprenorphine stabilisation for 6 weeks followed by 3-week taper (n = 57)
Maintenance buprenorphine (n = 56) for 14 weeks

Outcomes

Illicit opioid use, retention, and re-initiation of buprenorphine treatment

Notes

Quote: “Dr Fiellin has received honoraria for serving on expert advisory boards to
monitor for diversion, misuse, and abuse of buprenorphine for Pinney Associates and
ParagonRx and has received honoraria from the American Society of Addiction Medicine
to serve as the medical director of the Physician Clinical Support Systems for Buprenorphine and Primary Care and from the American Academy of Addiction Psychiatry to
serve as a consultant to the Physician Clinical
Support Systems for Buprenorphine and Opioids. Drs Schottenfeld and Moore received
support from the Connecticut Mental Health Center, State of
Connecticut. Dr Barry has received compensation for expert testimony addressing addiction and pain. No other disclosures were reported”
Funding was received from NIDA and a pharmaceutical company, Reckitt-Benckiser
Pharmaceuticals, provided
buprenorphine through the NIDA

Risk of bias
Bias

Risk of bias
Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “After the induction and stabilization period, patients were randomly assigned in a 1:1 ratio to receive taper or
maintenance therapy (each described below). An urn randomisation procedure under the control of an investigator (B.A.M.
) who was not involved with enrolment or
assessment for eligibility was used to ensure
that the groups were similar with regard
to current cocaine abuse and urine samples
with findings negative for opioids and cocaine at the time of randomisation”

Allocation concealment (selection bias)

Quote: “Treatment allocation was communicated by an investigator not involved in
assessment for eligibility or randomization
who notified each patient of his or her treatment assignment in a sequential manner”

Low risk

Blinding of participants and personnel High risk
(performance bias) Objective measures

Quote: “Open label randomized clinical
trial”

Blinding of outcome assessor (detection High risk
bias) Subjective outcomes

Quote: “Open label randomized clinical
trial”
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Fiellin 2014

(Continued)

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Quote: “Open label randomized clinical
trial”

Incomplete outcome data (attrition bias)
All outcomes

High risk

Quote: “Patients in the taper group provided fewer urine samples than those in the
maintenance group (57.3% vs 78.2%; P =
.001). The results regarding the patient-reported frequency of illicit opioid use are
based on 1044 assessments of the 1582 total possible assessments (66.0%) had all patients remained in treatment for the entire
14-week trial. Patients in the taper group
completed fewer patient-reported assessments than those in the maintenance group
(56.9% vs 76.3%; P < .001)”

Selective reporting (reporting bias)

Unclear risk

Clinicaltrials.gov indicated some measures
that were collected were not included in the
primary outcome paper (e.g. reductions in
HIV risk; patient satisfaction, costs of services). The main outcomes that would be
expected to be reported in a study of this
type were included in the main outcome
paper, suggesting that this may not represent bias

D’Onofrio 2015
Methods

Randomised controlled trial (open label) of opioid dependent people presenting at emergency departments

Participants

Included in analyses were unpublished data for participants where a pharmaceutical
opioid was the primary opioid used (n = 82). The main study recruited participants who
were 75% male with a mean age of 31.4 years (SD 10.6). Data on other substance use
for the subset that used pharmaceutical opioids were not available

Interventions

Referral to addiction treatment (n = 31)
Brief intervention and referral to addiction treatment (n = 24)
Brief intervention and commenced on buprenorphine as an inpatient (n = 27)

Outcomes

Primary outcome was engagement in addiction treatment on the 30th day following
randomisation. Secondary outcomes collected at 30 days included self reported number
of days of illicit opioid use in the past 7 days, urine toxicology for illicit opioid use, HIV
risk taking behaviour, and use of addiction treatment services
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D’Onofrio 2015

(Continued)

Notes

Quote: “The study was supported by grant 5R01DA025991 from the National Institute
on Drug Abuse (NIDA), and Reckitt-Benckiser Pharmaceuticals provided buprenorphine through NIDA”
Dr Fiellin reported having received honoraria from Pinney Associates “for serving on an
external advisory board monitoring the diversion and abuse of buprenorphine”

Risk of bias
Bias

Risk of bias
Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “A computerized stratified randomization procedure under the control of
an investigator (M.C.C.) who was not involved with enrolment or assessment for eligibility was used to ensure that the groups
were balanced with regard to sex, cocaine
use in the last 30 days, and primarily prescription opioid or heroin use”

Allocation concealment (selection bias)

Quote: “ A computerized stratified randomization procedure under the control of
an investigator (M.C.C.) who was not involved with enrolment or assessment...”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias) Objective measures

Quote: “Data on all outcomes were collected by research associates not involved in
the patients’ ED [emergency department]
care”
Not enough details were available to assess
risk (i.e. just because the participants were
not aware of the care in the ED did not
mean that they were not aware of the study
treatment)

Blinding of outcome assessor (detection Unclear risk
bias) Subjective outcomes

Quote: “Data on all outcomes were collected by research associates not involved in
the patients’ ED [emergency department]
care”
Not enough details were available to assess
risk (i.e. just because the participants were
not aware of the care in the ED did not
mean that they were not aware of the study
treatment)

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Quote: “Data on all outcomes were collected by research associates not involved in
the patients’ ED [emergency department]
care”
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D’Onofrio 2015

(Continued)

Not enough details were available to assess
risk (i.e. just because the participants were
not aware of the care in the ED did not
mean that they were not aware of the study
treatment)
Incomplete outcome data (attrition bias)
All outcomes

High risk

For the main outcome paper, most data
would not have been affected by attrition
due to the statistical methods used
Quote: “We used the mixed-models procedure repeated measures linear models to
evaluate the differences between baseline
and 30-day follow-up in the number of
days per week of illicit opioid use, HIV
risk behaviors, and inpatient addiction services across the study groups. This analytical approach uses all available data on each
randomized patient; therefore, all study patients, including those with missing data,
were included in the analyses; no imputations were required”
This suggests that for the main outcome paper low risk would exist; however, authors
reported that there were more missing data
for the non-opioid agonist group, suggesting analyses presented in this review may
be affected by attrition bias

Selective reporting (reporting bias)

Low risk

All measures prospectively reported on
Clinicaltrials.gov were reported in the main
outcome paper, in addition to those that
would be usually expected in this type of
study

HIV: human immunodeficiency virus; n: number of participants; NIDA: National Institute on Drug Abuse; SD: standard deviation.

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Amass 1994

No opioid maintenance condition as per definition of maintenance in protocol

Anglin 2007

Participants were heroin dependent
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(Continued)

Batki 1998

Study was not a randomised controlled trial

Cameron 2006

Unable to determine if participants were dependent on pharmaceutical opioids

Chopra 2009

All participants received buprenorphine (i.e. not randomised to different opioid agonists, and no non-agonist
group), randomised to different conditions of contingency management to promote abstinence from illicit
opioid use

Eder 1998

Study participants were primarily heroin dependent

Fiellin 2006

All groups received buprenorphine, that is there was no non-agonist comparison group

Fischer 1999

Study participants were primarily heroin dependent

Fudala 2003

Study participants were primarily heroin dependent

Gossop 2001

Study was not a randomised controlled trial design

Gruber 2008

Participants were primarily using heroin

Hoffmann 2014

Observational study (not a randomised controlled trial)

Johnson 1992

Participants were primarily using heroin

Johnson 1995

Participants were primarily using heroin

Johnson 2000

Participants were primarily using heroin

Kakko 2003

Participants were primarily using heroin

Karp-Gelernter 1982

Participants were primarily using heroin

Kristensen 2005

Sub-analyses of participants that used only pharmaceutical opioids was not possible, though it was confirmed
that there were participants that used a combination of heroin and pharmaceutical opioids

Liebschutz 2013

Too few participants (< 10) were using only pharmaceutical opioid, precluding meaningful comparisons

Ling 1996

Participants were primarily using heroin

Ling 1998

Participants were primarily using heroin

Ling 2010

Data not available to perform analyses on only those participants who were dependent on pharmaceutical
opioids

Longshore 2005

Participants were primarily using heroin

Maremmani 1999

Unable to confirm if study met inclusion criteria from information available
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McKenzie 2012

Participants were primarily using heroin

Montoya 2004

Participants were primarily using heroin

Petitjean 2001

Full text described sample in terms of their heroin use, unable to confirm with authors if any participants
were primarily pharmaceutical opioid dependent people

Piralishvili 2015

Unclear if participants were dependent only on pharmaceutical opioids

Reimer 2011

Participants were primarily using heroin

Robertson 2006

Published paper did not indicate the primary opioid used by study participants, unable to confirm with study
authors

Rosenthal 2013

Data not available to perform analyses on only those participants who were dependent on pharmaceutical
opioids

Sees 2000

Participants were described as primarily using heroin. Unable to confirm with study authors if there were any
pharmaceutical opioid dependent participants recruited

Sigmon 2013

Study was not of maintenance opioid treatment (all participants received different duration taper)

Stitzer 1983

All participants received detoxification, no maintenance comparison

Strain 1996

Participants were primarily using heroin

Strang 2000

Participants were primarily using heroin

Tennant 1982

Study design was not a randomised controlled trial

Uehlinger 1998

Unable to confirm if any participants were dependent on pharmaceutical opioids

Weiss 2011

All participants received buprenorphine (no non-buprenorphine control group). Participants were randomised
to receive enhanced counselling versus standard care
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DATA AND ANALYSES

Comparison 1. Full opioid agonists versus different full opioid agonists or partial opioid agonists

Outcome or subgroup title
1 Days of unsanctioned opioid use
2 Opioid positive urine drug
screen at treatment completion
3 Self reported substance use (end
of treatment)
4 Retention
5 Pain
6 Risk behaviours
7 Adverse effects
8 Physical health
9 Psychological health

No. of
studies

No. of
participants

1
2

129
196

Mean Difference (IV, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

-1.41 [-3.37, 0.55]
0.81 [0.56, 1.18]

2

155

Risk Ratio (M-H, Random, 95% CI)

0.37 [0.08, 1.63]

3
2
1
2
1
1

360
153
170
196
127
127

Risk Ratio (M-H, Random, 95% CI)
Std. Mean Difference (IV, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)

0.69 [0.39, 1.22]
0.11 [-0.22, 0.43]
0.52 [0.02, 12.64]
1.10 [0.64, 1.91]
1.28 [-3.83, 6.39]
-2.13 [-10.06, 5.80]

Statistical method

Effect size

Comparison 2. Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological
treatment

Outcome or subgroup title
1 Days of unsanctioned opioid use
2 Opioid positive (per urine drug
screen, last week of treatment
maintenance)
3 Self reported opioid use at
treatment completion (past 30
days)
4 Retention
5 Pain (some to extreme pain or
discomfort)
6 Risk behaviours
7 Adverse events
8 Physical health
9 Psychological health (moderate
to extremely anxious or
depressed)

No. of
studies

No. of
participants

Statistical method

2
3

133
206

Std. Mean Difference (IV, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

-0.31 [-0.66, 0.04]
0.63 [0.43, 0.91]

3

204

Risk Ratio (IV, Random, 95% CI)

0.54 [0.31, 0.93]

3
1

247
36

Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

0.33 [0.23, 0.47]
0.52 [0.27, 1.01]

2
2
1
1

117
166
36
36

Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

0.39 [0.04, 3.67]
0.19 [0.06, 0.57]
31.08 [12.40, 49.76]
0.89 [0.53, 1.50]
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Analysis 1.1. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 1 Days of unsanctioned opioid use.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 1 Days of unsanctioned opioid use

Study or subgroup

Methadone

Saxon 2013

Total (95% CI)

Mean
Difference

Buprenorphine

N

Mean(SD)

N

Mean(SD)

53

1.51 (4.972)

76

2.92 (6.381)

53

Weight

IV,Random,95% CI

Mean
Difference
IV,Random,95% CI

76

100.0 %

-1.41 [ -3.37, 0.55 ]

100.0 %

-1.41 [ -3.37, 0.55 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 2 Opioid positive urine drug screen at treatment completion.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 2 Opioid positive urine drug screen at treatment completion

Study or subgroup

Neumann 2013
Saxon 2013

Total (95% CI)

Methadone

Buprenorphine

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

2/13

5/13

6.5 %

0.40 [ 0.09, 1.70 ]

25/66

46/104

93.5 %

0.86 [ 0.59, 1.25 ]

79

117

100.0 %

0.81 [ 0.56, 1.18 ]

Total events: 27 (Methadone), 51 (Buprenorphine)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 3 Self reported substance use (end of treatment).
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 3 Self reported substance use (end of treatment)

Study or subgroup

Methadone
n/N

n/N

Neumann 2013

0/13

5/13

21.4 %

0.09 [ 0.01, 1.49 ]

11/53

29/76

78.6 %

0.54 [ 0.30, 0.99 ]

66

89

100.0 %

0.37 [ 0.08, 1.63 ]

Saxon 2013

Total (95% CI)

Buprenorphine

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

Total events: 11 (Methadone), 34 (Buprenorphine)
Heterogeneity: Tau2 = 0.63; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 4 Retention.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 4 Retention

Study or subgroup

Methadone

Risk
Ratio(Nonevent)
MH,Random,95%
CI

Buprenorphine

Weight

Risk
Ratio(Nonevent)
MH,Random,95%
CI

n/N

n/N

Ahmadi 2003

57/68

40/68

31.1 %

0.39 [ 0.21, 0.72 ]

Neumann 2013

13/28

13/26

34.7 %

1.07 [ 0.64, 1.80 ]

Saxon 2013

51/66

72/104

34.2 %

0.74 [ 0.43, 1.26 ]

162

198

100.0 %

0.69 [ 0.39, 1.22 ]

Total (95% CI)

Total events: 121 (Methadone), 125 (Buprenorphine)
Heterogeneity: Tau2 = 0.17; Chi2 = 6.32, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 5 Pain.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 5 Pain

Study or subgroup

Methadone

Std.
Mean
Difference

Buprenorphine

Weight

N

Mean(SD)

N

Mean(SD)

Neumann 2013

13

88.6 (24.5)

13

87.4 (33.4)

17.6 %

0.04 [ -0.73, 0.81 ]

Saxon 2013

51

67.39 (26.535)

76

64.22 (26.464)

82.4 %

0.12 [ -0.24, 0.47 ]

Total (95% CI)

64

IV,Random,95% CI

Std.
Mean
Difference
IV,Random,95% CI

89

100.0 % 0.11 [ -0.22, 0.43 ]

Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 6 Risk behaviours.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 6 Risk behaviours

Study or subgroup

Saxon 2013

Total (95% CI)

Methadone

Buprenorphine

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

0/66

1/104

100.0 %

0.52 [ 0.02, 12.64 ]

66

104

100.0 %

0.52 [ 0.02, 12.64 ]

Total events: 0 (Methadone), 1 (Buprenorphine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 7 Adverse effects.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 7 Adverse effects

Study or subgroup

Methadone
n/N

n/N

Neumann 2013

9/13

8/13

94.7 %

1.13 [ 0.64, 1.97 ]

Saxon 2013

1/66

2/104

5.3 %

0.79 [ 0.07, 8.52 ]

79

117

100.0 %

1.10 [ 0.64, 1.91 ]

Total (95% CI)

Buprenorphine

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

Total events: 10 (Methadone), 10 (Buprenorphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 8 Physical health.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 8 Physical health

Study or subgroup

Methadone

Saxon 2013

Total (95% CI)

Mean
Difference

Buprenorphine

N

Mean(SD)

N

Mean(SD)

51

56.67 (13.904)

76

55.39 (15.134)

51

Weight

IV,Random,95% CI

Mean
Difference
IV,Random,95% CI

100.0 %

76

1.28 [ -3.83, 6.39 ]

100.0 % 1.28 [ -3.83, 6.39 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 9 Psychological health.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 9 Psychological health

Study or subgroup

Methadone

Saxon 2013

Total (95% CI)

Mean
Difference

Buprenorphine

N

Mean(SD)

N

Mean(SD)

51

60.71 (21.38)

76

62.84 (23.703)

51

Weight

Mean
Difference

100.0 %

-2.13 [ -10.06, 5.80 ]

IV,Random,95% CI

IV,Random,95% CI

100.0 % -2.13 [ -10.06, 5.80 ]

76

Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 1 Days of unsanctioned opioid use.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 1 Days of unsanctioned opioid use

Study or subgroup

BPN maintenance

Std.
Mean
Difference

Taper/TAU

Weight

N

Mean(SD)

N

Mean(SD)

D’Onofrio 2015

26

0.5 (1.2379)

38

1.25 (2.1982)

48.5 %

-0.40 [ -0.90, 0.11 ]

Fiellin 2014

43

2.05 (4.84)

26

3.32 (6.34)

51.5 %

-0.23 [ -0.72, 0.26 ]

Total (95% CI)

69

IV,Random,95% CI

Std.
Mean
Difference
IV,Random,95% CI

100.0 % -0.31 [ -0.66, 0.04 ]

64

Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 2 Opioid positive (per urine drug screen, last week of treatment
maintenance).
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 2 Opioid positive (per urine drug screen, last week of treatment maintenance)

Study or subgroup

BPN maintenance
n/N

n/N

D’Onofrio 2015

5/22

10/34

14.3 %

0.77 [ 0.30, 1.96 ]

31/56

47/57

75.4 %

0.67 [ 0.52, 0.87 ]

Woody 2008

3/19

10/18

10.3 %

0.28 [ 0.09, 0.87 ]

Total (95% CI)

97

109

100.0 %

0.63 [ 0.43, 0.91 ]

Fiellin 2014

Taper/TAU

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

Total events: 39 (BPN maintenance), 67 (Taper/TAU)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.42, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 3 Self reported opioid use at treatment completion (past 30 days).
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 3 Self reported opioid use at treatment completion (past 30 days)

Study or subgroup

BPN maintenance

Taper/TAU

n/N

n/N

6/26

12/38

25.1 %

0.73 [ 0.31, 1.70 ]

27/56

42/57

51.5 %

0.65 [ 0.48, 0.89 ]

Woody 2008

4/18

8/9

23.4 %

0.25 [ 0.10, 0.61 ]

Total (95% CI)

100

104

100.0 %

0.54 [ 0.31, 0.93 ]

D’Onofrio 2015
Fiellin 2014

Risk Ratio

Weight

IV,Random,95% CI

Risk Ratio
IV,Random,95% CI

Total events: 37 (BPN maintenance), 62 (Taper/TAU)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.18, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 4 Retention.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 4 Retention
Risk
Ratio(Nonevent)
MH,Random,95%
CI

Taper/TAU

Risk
Ratio(Nonevent)
MH,Random,95%
CI

Study or subgroup

BPN maintanence
n/N

n/N

D’Onofrio 2015

23/27

24/54

14.4 %

0.27 [ 0.10, 0.68 ]

Fiellin 2014

37/56

6/57

71.0 %

0.38 [ 0.26, 0.55 ]

Woody 2008

23/27

6/26

14.6 %

0.19 [ 0.08, 0.49 ]

Total (95% CI)

110

137

100.0 %

0.33 [ 0.23, 0.47 ]

Weight

Total events: 83 (BPN maintanence), 36 (Taper/TAU)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 6.03 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 5 Pain (some to extreme pain or discomfort).
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 5 Pain (some to extreme pain or discomfort)

Study or subgroup

BPN maintenance

Taper/TAU

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Woody 2008

7/19

12/17

100.0 %

0.52 [ 0.27, 1.01 ]

Total (95% CI)

19

17

100.0 %

0.52 [ 0.27, 1.01 ]

Total events: 7 (BPN maintenance), 12 (Taper/TAU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 6 Risk behaviours.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 6 Risk behaviours

Study or subgroup

BPN maintenance

Taper/TAU

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

D’Onofrio 2015

0/26

1/38

49.9 %

0.48 [ 0.02, 11.38 ]

Woody 2008

0/27

1/26

50.1 %

0.32 [ 0.01, 7.55 ]

Total (95% CI)

53

64

100.0 %

0.39 [ 0.04, 3.67 ]

Total events: 0 (BPN maintenance), 2 (Taper/TAU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 7 Adverse events.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 7 Adverse events

Study or subgroup

BPN maintenance

Taper/TAU

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Fiellin 2014

3/56

16/57

86.6 %

0.19 [ 0.06, 0.62 ]

Woody 2008

0/27

2/26

13.4 %

0.19 [ 0.01, 3.84 ]

Total (95% CI)

83

83

100.0 %

0.19 [ 0.06, 0.57 ]

Total events: 3 (BPN maintenance), 18 (Taper/TAU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 8 Physical health.
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 8 Physical health

Study or subgroup

BPN maintenance
N

Woody 2008

Total (95% CI)

Mean
Difference

Taper/TAU
Mean(SD)

19 82.37 (23.78)

19

N

Mean(SD)

Weight

Mean
Difference

100.0 %

31.08 [ 12.40, 49.76 ]

IV,Random,95% CI

IV,Random,95% CI

17 51.29 (32.23)

17

100.0 % 31.08 [ 12.40, 49.76 ]

Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 9 Psychological health (moderate to extremely anxious or depressed).
Review:

Opioid agonist treatment for pharmaceutical opioid dependent people

Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 9 Psychological health (moderate to extremely anxious or depressed)

Study or subgroup

BPN maintenance

Woody 2008

Taper/TAU

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

11/19

11/17

100.0 %

0.89 [ 0.53, 1.50 ]

19

17

100.0 %

0.89 [ 0.53, 1.50 ]

Total (95% CI)

Total events: 11 (BPN maintenance), 11 (Taper/TAU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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APPENDICES
Appendix 1. Search strategies 2015
Cochrane Drugs and Alcohol Group (CDAG) Specialised Register of Trials
1 (((prescript* OR prescrib* OR pharmaceutical) NEAR (opioid* OR opiate*))) AND (INREGISTER)
2 (((opiate* OR opioid* OR morphin* OR morfin* OR narcot*) NEAR (abuse* OR abusing OR addict* OR misus* OR depend*
OR disorder*)):TI:AB) AND (INREGISTER)
3 ((opiate* OR opioid*):XDI) AND (INREGISTER)
4 #2 AND #3
5 #1 AND #4
6 ((prescript* OR prescrib* OR pharmaceutical):XDI) AND (INREGISTER)
7 #5 OR #6
Cochrane Central Register of Controlled Trials (CENTRAL)
1. MESH DESCRIPTOR Opioid-Related Disorders EXPLODE ALL TREES
2. (((opiate* OR opioid* OR morphin* OR morfin* OR narcot*) NEAR (abuse* OR abusing OR addict* OR misus* OR depend*
OR disorder*))):TI,AB,KY
3. #1 OR #2
4. (((opioid* OR opiat*) NEAR analges*)):TI,AB,KY
5. ((prescript* OR prescrib* OR pharmaceutical) NEAR (opioid* OR opiate*)):TI,AB,KY
6. MESH DESCRIPTOR Prescription Drugs EXPLODE ALL TREES
7. MESH DESCRIPTOR Narcotics
8. MESH DESCRIPTOR Analgesics, Opioid EXPLODE ALL TREES
9. #4 OR #5 OR #6 OR #7 OR
10. #3 AND #9
PubMed
1. “Opioid-Related Disorders”[MeSH]
2. ((opiate*[tiab] OR opioid*[tiab] OR morphin*[tiab] OR morfin*[tiab] OR narcot*[tiab]) AND (abuse*[tiab] OR abusing[tiab]
OR addict*[tiab] OR misus*[tiab] OR depend*[tiab] OR disorder*[tiab]))
3. #1 OR #2
4. “Analgesics, Opioid”[MeSH]
5. “Narcotics”[MeSH]
6. ((opioid*[tiab] OR opiat*[tiab]) AND analges*[tiab])
7. “Prescription Drugs”[MeSH]
8. ((prescript*[tiab] OR prescrib*[tiab] OR pharmaceutical[tiab]) AND (opioid*[tiab] OR opiate*[tiab]))
9. #4 OR #5 OR #6 OR #7 OR #8
10. randomized controlled trial [pt]
11. controlled clinical trial [pt]
12. randomized [tiab]
13. placebo [tiab]
14. drug therapy [sh]
15. randomly [tiab]
16. trial [tiab]
17. groups [tiab]
18. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
19. animals [mh] NOT humans [mh]
20. #18 NOT #19
21. #3 AND #9 AND #20
EMBASE
opiate addiction’/exp OR ((opiate* OR opioid* OR morphin* OR morfin* OR narcot*) NEAR/3 (abuse* OR abusing OR addict* OR
misus* OR depend* OR disorder*)):ab,ti AND (’narcotic analgesic agent’/exp OR ’narcotic agent’/exp OR (analges* NEAR/6 (opioid*
OR opiat*)):ab,ti OR ’prescription drug’/exp OR ((prescript* OR prescrib* OR pharmaceutical) NEAR/6 (opioid* OR opiate*)):ab,ti)
AND (’crossover procedure’/exp OR ’double blind procedure’/exp OR ’single blind procedure’/exp OR ’controlled clinical trial’ OR
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’clinical trial’/exp OR placebo:ab,ti OR ’double blind’:ab,ti OR ’single blind’:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:
ab,ti OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti) OR ’randomized controlled trial’/exp)
CINAHL
S19 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18
S18 TI placebo* or AB placebo*
S17 TI random* allocat* or AB random* allocat*
S16 MH “Random Assignment”
S15 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S14 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S13 TI clinic* N1 trial* or AB clinic* N1 trial*
S12 PT Clinical trial
S11 MH “Clinical Trials+”
S10 S3 AND S9
S9 S4 OR S5 OR S6 OR S7 OR S8
S8 TX (prescript* or prescrib* or pharmaceutical) N6 (opioid* or opiate*)
S7 (MH “Drugs, Prescription”)
S6 TX (analges* N6 (opioid* or opiate*))
S5 MH “Analgesics, Opioid+”
S4 (MH “Narcotics+”)
S3 S1 OR S2
S2 TX (opiate* or opioid* or morphin* or morfin* or narcot*) N6 (abuse* or abusing or addict* or misus* or depend* or disorder*)
S1 (MH “Substance Use Disorders+”)
ISI Web of Science
7. #6 AND #2 AND #1
6. #5 OR #4 OR #3
5. TOPIC: (“prescription drugs”)
4. TS=((prescript* or prescrib* or pharmaceutical) NEAR/3 (opioid* or opiate*))
3. TS=((opioid* or opiat*) near/2 analges*)
2. TS=(((opiate* or opioid* or morphin* or morfin* or narcot*) NEAR/6 (abuse* or abusing or addict* or misus* or depend*)))
1. TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR TS=
follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)
PsycINFO
1. exp Drug Dependency/ or exp Drug Abuse/ or exp Drug Withdrawal/ or exp Drug Addiction/
2. addiction/
3.((narcotic$ or opiate$ or opioid$ or morphin$) adj3 (misuse or abuse$ or addict$ or depend$)).ti,ab.
4. 1 or 2 or 3
5. ((opioid* or opiat*) adj3 analges*).ti,ab.
6. narcotic agonists/ or narcotic drugs/ or apomorphine/ or meperidine/ or methadone/ or tramadol/ or analgesic drugs/
7. exp Morphine/ or exp Analgesia/ or exp Analgesic Drugs/
8. prescription drugs/
9. ((prescript* or prescrib* or pharmaceutical) adj3 (opioid* or opiate*)).ti,ab.
10. or/5-9
11. 4 and 10
12. animals/ not (animals/ and human$.mp.)
13. (animal/ or animals/) not ((animal/ and human/) or (animals/ and humans/))
14 .(animal not (animal and human)).po.
15. random$.mp.
16. trial.mp.
17. groups.mp.
18. placebo.mp.
19. exp Clinical Trials/
20. or/15-19
21. 20 not (12 or 13 or 14)
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22. 11 and 21

Appendix 2. Criteria for risk of bias assessment

Item

Judgement

Random sequence generation (selection Low risk
bias)

Allocation concealment (selection bias)

Description
The investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation

High risk

The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention

Unclear risk

Insufficient information about the sequence generation process to permit
judgement of low or high risk

Low risk

Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based, and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes

High risk

Investigators enrolling participants could possibly foresee assignments
because one of the following methods was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure

Unclear risk

Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement

Blinding of participants and providers (per- Low risk
formance bias)
Objective outcomes

High risk

No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding; or
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
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(Continued)
Unclear risk
Blinding of participants and providers (per- Low risk
formance bias)
Subjective outcomes

Blinding of participants and providers and unlikely that the blinding
could have been broken

High risk

No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

Blinding of outcome assessor (detection Low risk
bias)
Objective outcomes

No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

Blinding of outcome assessor (detection Low risk
bias)
Subjective outcomes

Incomplete outcome data (attrition bias)
For all outcomes except retention

Insufficient information to permit judgement of low or high risk

No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

Low risk

No missing outcome data
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias)
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a clinically relevant
impact on the intervention effect estimate
For continuous outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes not enough
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(Continued)

to have a clinically relevant impact on observed effect size
Missing data have been imputed using appropriate methods
All randomised participants are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and cointerventions (intention to treat)

Selective reporting (reporting bias)

High risk

Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size
’As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation

Unclear risk

Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop-out not reported for each group)

Low risk

The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)

High risk

Not all of the study’s pre-specified primary outcomes have been reported
One or more primary outcomes is reported using measurements, analysis
methods, or subsets of the data (e.g. subscales) that were not pre-specified
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect)
One or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study

Unclear risk

Insufficient information to permit judgement of low or high risk
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
We had originally intended to include any studies with pharmaceutical opioid dependent people in analyses if they could provide data
for only those participants that were dependent on pharmaceutical opioids. On contacting authors, we became aware that some studies
had only recruited very small numbers (e.g. two or three participants) of people who were dependent on pharmaceutical opioids,
preventing meaningful analyses. For this reason, we added the criteria that at least 10 people must have been recruited who were
dependent on pharmaceutical opioids to warrant re-analyses of the data for those people.
We did not produce funnel plots to examine risk of bias because of the small number of studies identified.

INDEX TERMS
Medical Subject Headings (MeSH)
∗ Prescription

Drug Misuse; Analgesics, Opioid [therapeutic use]; Buprenorphine [∗ therapeutic use]; Methadone [∗ therapeutic use];
Narcotics [ therapeutic use]; Opiate Substitution Treatment [∗ methods]; Opioid-Related Disorders [∗ drug therapy]; Randomized
Controlled Trials as Topic
∗

MeSH check words
Humans
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